• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Advanced statistical methods and designs for clinical trials for COVID-19.

作者信息

Shan Guogen, Wang Weizhen

机构信息

Epidemiology and Biostatistics Program, Department of Environmental and Occupational Health, School of Public Health, University of Nevada Las Vegas, Las Vegas, 89154, NV, USA.

Department of Mathematics and Statistics, Wright State University, Dayton, OH 45435, USA.

出版信息

Int J Antimicrob Agents. 2021 Jan;57(1):106167. doi: 10.1016/j.ijantimicag.2020.106167.

DOI:10.1016/j.ijantimicag.2020.106167
PMID:33408032
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7833547/
Abstract
摘要

相似文献

1
Advanced statistical methods and designs for clinical trials for COVID-19.用于新型冠状病毒肺炎临床试验的先进统计方法与设计
Int J Antimicrob Agents. 2021 Jan;57(1):106167. doi: 10.1016/j.ijantimicag.2020.106167.
2
Effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial.羟氯喹治疗新型冠状病毒肺炎的疗效评估：一项开放标签非随机临床试验的二次分析
Int J Antimicrob Agents. 2021 Jan;57(1):106172. doi: 10.1016/j.ijantimicag.2020.106172.
3
Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a meta-analysis.羟氯喹和阿奇霉素对新型冠状病毒肺炎患者严重急性呼吸综合征冠状病毒2清除率的影响：一项荟萃分析
Int J Antimicrob Agents. 2021 Jan;57(1):106240. doi: 10.1016/j.ijantimicag.2020.106240.
4
Safety profile of hydroxychloroquine and azithromycin combined treatment in COVID-19 patients.羟氯喹啉与阿奇霉素联合治疗COVID-19患者的安全性概况。
Int J Antimicrob Agents. 2021 Jan;57(1):106236. doi: 10.1016/j.ijantimicag.2020.106236.
5
Uncertain effects of hydroxychloroquine and azithromycin on SARS-Cov-2 viral load.羟氯喹和阿奇霉素对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）病毒载量的影响尚不确定。
Int J Antimicrob Agents. 2021 Jan;57(1):106169. doi: 10.1016/j.ijantimicag.2020.106169.
6
Use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature.近期文献不支持将羟氯喹与阿奇霉素联合用于新冠肺炎患者。
Int J Antimicrob Agents. 2021 Jan;57(1):106174. doi: 10.1016/j.ijantimicag.2020.106174.
7
Letter to the editor about "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".致编辑的信：关于“羟氯喹和阿奇霉素作为治疗新型冠状病毒肺炎的药物：一项开放标签非随机临床试验的结果”
Int J Antimicrob Agents. 2021 Jan;57(1):106171. doi: 10.1016/j.ijantimicag.2020.106171.
8
Referring to the study: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial.参考研究：《羟氯喹和阿奇霉素治疗新型冠状病毒肺炎：一项开放标签非随机临床试验的结果》
Int J Antimicrob Agents. 2021 Jan;57(1):106176. doi: 10.1016/j.ijantimicag.2020.106176.
9
Focus on clinical outcomes of "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".关注“羟氯喹和阿奇霉素治疗新型冠状病毒肺炎：一项开放标签非随机临床试验的结果”的临床结局。
Int J Antimicrob Agents. 2021 Jan;57(1):106175. doi: 10.1016/j.ijantimicag.2020.106175.
10
Clinical efficacy and safety profile of hydroxychloroquine and azithromycin against COVID-19.羟氯喹啉和阿奇霉素治疗新型冠状病毒肺炎的临床疗效及安全性概况
Int J Antimicrob Agents. 2021 Jan;57(1):106242. doi: 10.1016/j.ijantimicag.2020.106242.

引用本文的文献

1
Functional and Clinical Outcomes in Acute Wound Management: Measuring the Impact of Negative Pressure Wound Therapy and Specialized Physical Therapy.急性伤口管理中的功能与临床结局：评估负压伤口治疗及专业物理治疗的影响
Life (Basel). 2025 Mar 21;15(4):511. doi: 10.3390/life15040511.
2
Continuity corrected score confidence interval for the difference in proportions in paired data.配对数据中比例差异的连续性校正得分置信区间。
J Appl Stat. 2022 Sep 14;51(1):139-152. doi: 10.1080/02664763.2022.2118245. eCollection 2024.
3
Response adaptive randomization design for a two-stage study with binary response.两阶段二分类反应研究的响应适应性随机分组设计。
J Biopharm Stat. 2023 Sep 3;33(5):575-585. doi: 10.1080/10543406.2023.2170399. Epub 2023 Feb 3.
4
Effects of dose change on the success of clinical trials.剂量变化对临床试验成功率的影响。
Contemp Clin Trials Commun. 2022 Sep 5;30:100988. doi: 10.1016/j.conctc.2022.100988. eCollection 2022 Dec.
5
Conservative confidence intervals for the intraclass correlation coefficient for clustered binary data.聚类二元数据组内相关系数的保守置信区间。
J Appl Stat. 2021 Apr 2;49(10):2535-2549. doi: 10.1080/02664763.2021.1910939. eCollection 2022.
6
New Confidence Intervals for Relative Risk of Two Correlated Proportions.两个相关比例相对风险的新置信区间
Stat Biosci. 2023;15(1):1-30. doi: 10.1007/s12561-022-09345-7. Epub 2022 May 20.
7
Machine learning methods to predict amyloid positivity using domain scores from cognitive tests.利用认知测试的领域评分进行机器学习预测淀粉样蛋白阳性。
Sci Rep. 2021 Mar 1;11(1):4822. doi: 10.1038/s41598-021-83911-9.
8
Optimal two-stage designs based on restricted mean survival time for a single-arm study.基于单臂研究受限平均生存时间的最优两阶段设计。
Contemp Clin Trials Commun. 2021 Jan 23;21:100732. doi: 10.1016/j.conctc.2021.100732. eCollection 2021 Mar.

本文引用的文献

1
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.羟氯喹和阿奇霉素治疗 COVID-19：一项开放标签非随机临床试验的结果。
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.